The primary objective of this trial was to compare the efficacy of flexibly dosed aripiprazole with that of placebo in reducing serious behavioral problems, specifically irritability, agitation, and self-injurious behavior, in children and adolescents with a diagnosis of AD, as measured by change from baseline to endpoint on the Irritability Subscale of the Aberrant Behavior Checklist (ABC).